Full text is available at the source.
Abstract
Retatrutide has demonstrated significant reductions in body weight and improved glycemic control outcomes in clinical trials.
- Retatrutide is a triple agonist targeting glucagon receptors, gastric inhibitory polypeptide, and glucagon-like peptide-1.
- Its mechanism likely involves increased insulin secretion, better glucose regulation, and appetite control.
- Clinical trials across phases 1 to 3 showed significant efficacy in weight loss and glycemic control.
- Retatrutide may help reduce cardiovascular risk factors and address liver disease linked to metabolic dysfunction.
- Further research is necessary to assess its long-term safety and potential roles in various populations.
Simplified